PRIME’s technology for the development of novel veterinary vaccines
Boehringer Ingelheim and Biotech Startup enter a strategic collaboration
Prime Vector Technologies (PRIME), a Biotech Startup focusing on the development of viral vector based vaccines, and Boehringer Ingelheim, a leading global research-based pharmaceutical company, announce that they have entered a strategic collaboration, option and licence agreement. The collaboration is set to establish and test up to eight different vaccine candidates against a variety of veterinary diseases within the next three years using PRIME’s proprietary Orf virus (ORFV) platform technology.

Symbolic image
pixabay.com
ORFV platform
ORFV belongs to the family of poxviridae and possesses an excellent safety profile, stable expression of multiple transgenes simultaneously and is well suited for the possibility of multiple dose immunizations. Prior to the collaboration agreement, the platform was developed at the University of Tuebingen, and showed to be effective in various host animals against different infectious diseases. “After so many years of research and development on our platform, we are proud to receive the commitment to and trust in our technology from Boehringer Ingelheim as one of the world’s leading pharmaceutical companies in the animal health market. With this strong partner, we are excited to advance our technology and to enhance our contribution to improving animal health,” says Dr. Ralf Amann, CEO of PRIME.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
Last viewed contents
Genetic Study Shows Direct Link Between Vitamin D and MS Susceptibility Gene
Teva announces successful results of Phase III with oral laquinimod for multiple sclerosis
Paul_Clemens_von_Baumgarten
ATLAS Biolabs participates in two European research projects to investigate DNA repair and cellular aging

Many proteins must set to work so as to activate fat - New insights into the fuctions of fat metabolism
Amarna Therapeutics Teaming Up with Austrian CBmed in the Development of Immunotherapies
Nonsyndromic_deafness

Defective Epithelial Barriers Linked to Two Billion Chronic Diseases - Rise in allergic and autoimmune conditions
